An interventional study of Trillium Full Face Mask and AirFit F20 in Obstructive Sleep Apnea, sponsored by Philips Clinical & Medical Affairs Global. Completed at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sleep Apnea, Obstructive by Philips — none open to participants now, none under way, none of them phase 3. Sleep Apnea, Obstructive · Philips.
Among the 13 studies in Sleep Apnea, Obstructive by Philips, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 13 with no phase, and was the 12th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →None of the 13 studies in Sleep Apnea, Obstructive by Philips is open now. The open studies under Sleep Apnea, Obstructive, anywhere →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 21 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
This study's enrollment of 40 is below the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 45 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Philips Clinical & Medical Affairs Global, one of the names counted as Philips. Under that name alone:
Philips Clinical & Medical Affairs Global is the lead sponsor of 86 studies on the registry; 25 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 13 (81%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sleep Apnea, Obstructive by Philips, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a single-center, open-label randomized crossover design pilot study to evaluate the clinical safety, clinical performance, and clinical benefit of the Trillium full face mask
This will be a single-center, open-label randomized crossover design pilot study to evaluate the clinical safety, clinical performance, and clinical benefit of the Trillium FFM (Full Face Mask). Subjects meeting all eligibility criteria will be enrolled and will be randomized. Based on their randomization, subjects will be asked to use either a new AirFit F20 mask or the Trillium investigational mask for approximately 15 consecutive days (±3 days) of use. They will return for a follow-up visit to complete surveys about their experience during the first treatment period. Subjects will then be crossed over to the other mask (i.e., AirFit F20 or Trillium) per the randomization assignment. Following a second 15-day period of home use, subjects will return for a final visit to complete surveys about their experience in the second treatment period and conclude participation in the investigation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient or patient's household member, caregiver or bed partner in close vicinity that have implanted devices that may be affected by magnets, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will use Trillium for the first treatment period and AirFit F20 for the second treatment period
Device: Trillium Full Face Mask
Participants will use AirFit F20 for the first treatment period and Trillium for the second treatment period
Device: AirFit F20
The Trillium Full Face Mask (FFM) (Philips Respironics, Murrysville, PA) is an over-the-nose, full-face mask with the hose connection in the front. The mask is used with a positive airway pressure (PAP) therapy device and covers both the nose and mouth, ensuring pressurized air is delivered directly into the patient's airways.
Also known as: Trillium
The AirFit F20 (ResMed, San Diego, California) is an externally placed vented mask covering the mouth and the nose of the patient. It provides a seal such that pressure from a positive pressure source is directed to the patient's nose and/or mouth. The mask connects via a standard conical connector to a conventional air delivery hose, which in turn connects to the positive pressure source. The mask is held in place with an adjustable headgear that straps the mask to the face. The AirFit F20 mask system comprises four subassemblies: cushion, frame, elbow and headgear. The elbow incorporates the vent array and anti-asphyxia valve safety features.
Median Unintentional Leak During Trillium Mask Use
Unintentional leak was obtained from positive airway pressure device data during the approximately 15-day Trillium mask treatment period. For each participant, the median unintentional leak was calculated. The reported result is the mean of the participant-level median values and its 95% confidence interval. Lower values indicate less unintentional leak. The result was considered acceptable if the upper limit of the 95% confidence interval was less than 24 L/min.
Time frame: During the approximately 15-day Trillium mask treatment period
Expected Adverse Device Effects
Number of participants with expected adverse device effects during the approximately 15-day Trillium mask treatment period. Expected effects included skin effects, oronasal dryness, eye-related side effects, anxiety, allergic reaction, and headache.
Time frame: Approximately 15-day Trillium mask treatment period
Comfort of Breathing During Trillium Mask Use
After the Trillium mask treatment period, participants rated their satisfaction with comfort of breathing on a scale from 0 to 10, where 0 indicated extremely dissatisfied, 5 indicated neutral, and 10 indicated extremely satisfied. The reported result is the mean rating across participants and its 95% confidence interval. Higher scores indicate greater satisfaction. The result was considered acceptable if the lower limit of the 95% confidence interval was at least 7.5.
Time frame: After approximately 15-day Trillium mask treatment period
Average Daily PAP Device Use Across All Study Days
Average daily PAP device use was calculated for each participant across all study days in each treatment period, including days with no recorded device use, and expressed in hours per day. The reported results are the mean and 95% confidence interval across participants for each mask. Higher values indicate greater device use.
Time frame: During each approximately 15-day mask treatment period
Apnea-Hypopnea Index (AHI)
Residual apnea-hypopnea index was obtained from PAP device data during each treatment period and expressed as the number of apnea and hypopnea events per hour. The reported results are the mean and 95% confidence interval across participants for each mask. Lower values indicate fewer residual respiratory events.
Time frame: During each approximately 15-day mask treatment period
Epworth Sleepiness Scale Total Score
The Epworth Sleepiness Scale is an 8-item questionnaire assessing the likelihood of dozing during common daily situations. Each item is scored from 0 (would never doze) to 3 (high chance of dozing). Item scores are summed to produce a total score ranging from 0 to 24 points. Higher scores indicate greater daytime sleepiness.
Time frame: After each approximately 15-day mask treatment period
EQ-5D-3L Summary Index
The EQ-5D-3L (European Quality of Life-5D) is a generic measure of health status. The descriptive system assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels (1 = no problems, 2 = some problems, and 3 = extreme problems). Responses were converted to a single summary index using the U.S. value set. Index scores range from -0.109 to 1.000, with higher scores indicating better health status and 1 representing full health.
Time frame: After each approximately 15-day mask treatment period
A total of 40 participants were enrolled, and 38 completed for a safety analysis data set of n=40 and a performance analysis data set of n=38 participants. The first participant was enrolled on 15-Jul-2025 and last participant completed the study on 19-Aug-2025. Participants were recruited from Florida Lung \& Sleep Associates
| Milestone | Trillium Then AirFit F20 Sequence | Airfit F20 Then Trillium Sequence |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 19 |
| Not completed | 1 | 1 |
Unintentional leak was obtained from positive airway pressure device data during the approximately 15-day Trillium mask treatment period. For each participant, the median unintentional leak was calculated. The reported result is the mean of the participant-level median values and its 95% confidence interval. Lower values indicate less unintentional leak. The result was considered acceptable if the upper limit of the 95% confidence interval was less than 24 L/min.
| L/min | Trillium |
|---|---|
| Median Unintentional Leak During Trillium Mask Use | 12.14 (5.10 to 19.19) |
Number of participants with expected adverse device effects during the approximately 15-day Trillium mask treatment period. Expected effects included skin effects, oronasal dryness, eye-related side effects, anxiety, allergic reaction, and headache.
| Participants | Trillium |
|---|---|
| Expected Adverse Device Effects | 0 |
After the Trillium mask treatment period, participants rated their satisfaction with comfort of breathing on a scale from 0 to 10, where 0 indicated extremely dissatisfied, 5 indicated neutral, and 10 indicated extremely satisfied. The reported result is the mean rating across participants and its 95% confidence interval. Higher scores indicate greater satisfaction. The result was considered acceptable if the lower limit of the 95% confidence interval was at least 7.5.
| points on a 0-10 scale | Trillium |
|---|---|
| Comfort of Breathing During Trillium Mask Use | 9.03 (8.44 to 9.61) |
Average daily PAP device use was calculated for each participant across all study days in each treatment period, including days with no recorded device use, and expressed in hours per day. The reported results are the mean and 95% confidence interval across participants for each mask. Higher values indicate greater device use.
| hours/day | Trillium | AirFit F20 |
|---|---|---|
| Average Daily PAP Device Use Across All Study Days | 6.62 (6.13 to 7.11) | 6.57 (6.07 to 7.06) |
Residual apnea-hypopnea index was obtained from PAP device data during each treatment period and expressed as the number of apnea and hypopnea events per hour. The reported results are the mean and 95% confidence interval across participants for each mask. Lower values indicate fewer residual respiratory events.
| events/hour | Trillium | AirFit F20 |
|---|---|---|
| Apnea-Hypopnea Index (AHI) | 2.28 (1.47 to 3.08) | 2.41 (1.30 to 3.51) |
The Epworth Sleepiness Scale is an 8-item questionnaire assessing the likelihood of dozing during common daily situations. Each item is scored from 0 (would never doze) to 3 (high chance of dozing). Item scores are summed to produce a total score ranging from 0 to 24 points. Higher scores indicate greater daytime sleepiness.
| points on a 0-24 scale | Trillium | AirFit F20 |
|---|---|---|
| Epworth Sleepiness Scale Total Score | 5.50 (4.07 to 6.93) | 5.92 (4.58 to 7.27) |
The EQ-5D-3L (European Quality of Life-5D) is a generic measure of health status. The descriptive system assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels (1 = no problems, 2 = some problems, and 3 = extreme problems). Responses were converted to a single summary index using the U.S. value set. Index scores range from -0.109 to 1.000, with higher scores indicating better health status and 1 representing full health.
| EQ-5D-3L index points | Trillium | AirFit F20 |
|---|---|---|
| EQ-5D-3L Summary Index | 0.88 (0.81 to 0.94) | 0.89 (0.83 to 0.94) |
Collected over During the approximately 15-day treatment period for each mask. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trillium | 0/39 (0%) | 1/39 (2.6%) | 0/39 (0%) |
| AirFit F20 | 0/39 (0%) | 0/39 (0%) | 1/39 (2.6%) |
| Event | Trillium | AirFit F20 |
|---|---|---|
| Bilateral lower extremity weaknessNervous system disorders | 1/39 | 0/39 |
| Event | Trillium | AirFit F20 |
|---|---|---|
| dizziness/diaphoresis/dyspneaGeneral disorders | 0/39 | 1/39 |
| Age, Continuous(years) | Trillium Then AirFit F20 Sequence | Airfit F20 Then Trillium Sequence | Total |
|---|---|---|---|
| Mean | 61.7 ± 14.15 | 57.9 ± 13.93 | 59.8 ± 13.99 |
| Sex: Female, Male(Participants) | Trillium Then AirFit F20 Sequence | Airfit F20 Then Trillium Sequence | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 13 | 16 | 29 |
| Race (NIH/OMB)(Participants) | Trillium Then AirFit F20 Sequence | Airfit F20 Then Trillium Sequence | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 7 |
| White | 17 | 15 | 32 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Trillium Then AirFit F20 Sequence | Airfit F20 Then Trillium Sequence | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 15 |
| Not Hispanic or Latino | 12 | 11 | 23 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2025 to primary completion in Aug 2025, 1 month.
Results were first posted in Sep 2026, 1 year 1 month after primary completion.
Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 1 month is below that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Philips Clinical & Medical Affairs Global →